comparative immunogenicity of hiv-1 clade c envelope proteins for primeboost studies比较primeboost研究分支c的hiv - 1包膜蛋白的免疫原性.pdf

Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies 1 1 1 2 1,3 Douglas H. Smith , Peggy Winters-Digiacinto , Misrach Mitiku , Sara O’Rourke , Faruk Sinangil , Terri 4 5 1,2 Wrin , David C. Montefiori , Phillip W. Berman * 1VaxGen, Inc., Brisbane, California, United States of America, 2 Baskin School of Engineering, University of California Santa Cruz, Santa Cruz, California, United States of America, 3 Global Solutions For Infectious Diseases, South San Francisco, California, United States of America, 4 Monogram Biosciences, South San Francisco, California, United States of America, 5 Duke University Medical School, Durham, North Carolina, United States of America Abstract Background: Previous clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization strategy involving priming with canarypox vCP1521 followed by boosting with rgp120 could provide significant, although modest, protection from HIV infection. Based on these results, there is renewed interest in the development of rgp120 based antigens for follow up vaccine trials, where this immunization approach can be applied to other cohorts at high risk for HIV infection. Of particular interest are cohorts in Africa, India, and China that are infected with clade C viruses. Methodology/Principal Findings: A panel of 10 clade C rgp120 envelope proteins was expressed in 293 cells, purified by immunoaffinity chromatography, and used to imm